



#6/KT
3/4
026.00231/A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: O'Brien et al.)
Serial No.: 09/846,506) Examiner: J. Schultz
Filed: May 1, 2001) Art Unit: 1635
For: USE OF CD63 INHIBITORS)

AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the August 13, 2002 office action,
please amend the above-identified patent application as
follows:

In the claims:

Please amend claim 5 as follows:

A'
5. (Amended) A method of treating human immunodeficiency
virus infection in a subject, the method comprising
administering to the subject an amount of a compound effective
to decrease levels of functional CD63 in cells of the subject.

REMARKS

In view of the above amendments and the following
remarks, reconsideration of the outstanding office action is
respectfully requested.

The rejection of claims 1-10 under 35 U.S.C. § 112
(first paragraph) for lack of written description is
respectfully traversed.

The basis for the U.S. Patent and Trademark Office's
("PTO") rejection of the claims is that the present